Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Precision Treatment Strategy for Recurrent High-grade Gliomas
NCT05473923Phase 1Active, not recruiting
- Sponsor
- Beijing Tiantan Hospital
- Start
- Aug 2022
- Primary completion
- Dec 2024
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in glioma, sponsored by Beijing Tiantan Hospital. Primary endpoint: The percentage of patients who accomplish the recommended regimen for at least 1 course at 24 months. Started Aug 2022; status: active, not recruiting.
02
Conditions
glioma
Beyond the preview
Go deeper on NCT05473923.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05473923.